NTRK1 and non-small cell lung carcinoma: Early clinical trials have evaluated the antitumour activity of new-generation TRK-inhibitors, such as selitrectinib [76] and repotrectinib [77], in NTRK-positive NSCLC patients who develop acquired resistance mutations to larotrectinib or entrectinib.